Trial Profile
A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HER-096 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Herantis Pharma
- 11 Aug 2020 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 According to a Herantis Pharma media release, this study is expected to to be completed in Q2/2020.
- 10 Jan 2020 Planned End Date changed from 30 Sep 2020 to 30 Jun 2020.